Investing.com - Emergent Biosolutions (NYSE: EBS) reported first quarter EPS of $0.590, $1.42 better than the analyst estimate of $-0.830. Revenue for the quarter came in at $300.4M versus the consensus estimate of $185.4M.
Guidance
Emergent Biosolutions sees FY 2024 revenue of $1,000.000M-$1.100B versus the analyst consensus of $1.020B.
Emergent Biosolutions's stock price closed at $1.93. It is up 19.140% in the last 3 months and down -76.660% in the last 12 months.
Emergent Biosolutions saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Emergent Biosolutions's stock price’s past reactions to earnings here.
According to InvestingPro, Emergent Biosolutions's Financial Health score is "weak performance".
Check out Emergent Biosolutions's recent earnings performance, and Emergent Biosolutions's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar